Here is some data from HSBC on Indian Rupee Versus USD and Euro
INR /USD, end-year 45.61 43.46 45.05 44.26 39.00 37.50[2008E] 36.00[2009E]
INR /EUR, end-year 55.25 59.11 53.14 58.36 56.55 50.63[2008E] 46.80[2009E]
Indian Equity Research and Investment Strategy
Here is some data from HSBC on Indian Rupee Versus USD and Euro
INR /USD, end-year 45.61 43.46 45.05 44.26 39.00 37.50[2008E] 36.00[2009E]
INR /EUR, end-year 55.25 59.11 53.14 58.36 56.55 50.63[2008E] 46.80[2009E]
India’s premier infrastructure lending company – IDFC was upgraded by Morgan Stanley research. They have set a new price target of Rs 200 on the stock. Here is Citi’s exclusive coverage on IDFC.
IDFC is entering a phase where all parts of revenue are doing well – loan growth is strong, spreads are improving and fees are very strong. For F2005-F2007, IDFC has delivered the best core earnings progression among Indian private banks and financial institutions at a 55% CAGR. This trend will continue, resulting in outperformance.
IDFC has launched the first tranche of its proposed US$2 bn project equity fund along with Citi. This will result in a doubling of assets under management in 1-2 months. Moreover, its investments in NSE is performing strongly. SSKI is two-third owned by IDFC is also performing well.
Based on earnings adjusted for recent capital issuance and new fund raising in project equity, consensus is expecting 4% YoY earnings growth in the rest of F2008. The actual numbers are likely to be higher and hence raise F2008 earnings estimates by 5%.
The stock is trading at 24.8x F2009E earnings – in line with private banks. However, private equity (PE) and proprietary investments are not contributing significantly to earnings but provide almost 30% of value. Hence, core valuations are lower at 19x (cheaper than private banks, with better earnings profile) and could rise, given strong earnings growth expectations.
In a separate development, Reliance Capital has launched an exclusive Consumer Finance Loan subsidiary.
Reliance Gold Exchange Traded Fund is an open ended Gold Exchange Traded Fund which will track the performance of Gold Bullion. The units issued under the scheme will represent the value of gold held in the scheme. It is designed to provide returns that, before expenses, closely correspond to the returns provided by domestic price of Gold.
NFO Opens: 15thOct,07
NFO Closes: 1stNov, 07
Investors looking to purchase Gold can invest in this fund. Questions and comments on Mutual Funds maybe sent to feedback @ dalalstreet. biz
Lehman Brothers have just released an equity research report initiating coverage on Indian IT stocks. Here is the overview before we get into the details. The report assumes USD pricing of Rs 36 and is Negative on the IT sector.
Infosys Technologies:
The macro environment is likely to remain unfavourable due to the appreciating rupee and a possible slowdown in the banking and financial services (BFS) vertical. Lehman estimates a 15.7% EPS CAGR for the next three years (FY07-FY10E) compared with 43.5% in the past three years. Volume growth and price hikes may be impacted negatively due to a cut in discretionary IT spend. The demand environment continues to be good; US dollar revenue CAGR of 35% for the next three years.
Tata Consultancy Services:
A 14% EPS CAGR for the next three years (FY07-FY10E) compared to 35.8% for the past three years. Volume growth and price hikes may be impacted negatively due to cuts in discretionary IT spending. The demand environment continues to be good, because US dollar revenue CAGR of 30.8% for the next three years.
Wipro:
Wipro continues to be hit by relatively slow growth in Telecom equipment manufacturing (TEM) and BPO segments. Lehman projects a 30.6% US dollar revenue CAGR for the company’s Global IT Services and Products business on an organic basis for the next three years compared with 35% for Infosys Technologies (INFY, 2-Equalweight) during the same period. Should result in an EPS CAGR of 15.6% for Wipro in FY07-FY10E.
Wipro has underperformed the most among tier-1 Indian IT stocks in the past five years. This will continue because margins to fall by more than 300bp for the next three years.
Satyam Computers:
Given the deteriorating environment, robust QoQ volume growth as witnessed in the past five quarters and price hikes could be pressured in FY09, in our view. Despite strong volume growth, we estimate an EPS CAGR of 13.4% for the next three years given our expectation of falling margins.
FIIs darling in India, Infosys has been deserted for the past quarter since the appreciation of the Indian rupee. Ahead of its results tomorrow, the stock is up 3% at Rs 2,120. Infact all the IT stocks are up on expectation of earnings revision since the cost of VISA pressure is accounted for in Q1.
A total of seven brokerages expect a between 0.58% fall to a 4.6% rise in Infosys’ consolidated net profit as per Indian GAAP to between Rs 1,072.70 crore to Rs 1128.70 crore in Q2 September 2007 compared to net profit of Rs 1,079 crore Q1 June 2007. They expect a between 6.8% to 9.7% growth in Infosys’ revenue at between Rs 4,028.60 crore to Rs 4,138.40 crore in Q2 September 2007 compared to revenue of Rs 3,773 crore in Q1 June 2007.
Infosys had cut EPS guidance in rupee terms to a growth of 15.6% to 16.8% compared to the earlier guidance of 20% to 22% growth. It had also slashed revenue guidance in rupee terms to 16.9% to 18.3%, from earlier guidance of a growth of 22.6% to 24.6%.
All the IT stocks are up on high expectations from Labour Arbitrage IT Services Company. Our analyst is of the view that, the rupee saga will continue and put pressure on IT services companies. Infact it is best to explore other companies such as Capital Goods, Construction and Finance in India.
Glenmark Pharmaceuticals has received final approval from the U.S. food and drug administration for the marketing the first generic version of trileptal (oxcarbazepine). The approval is for marketing oxcarbazapine tablets in three strengths – 150 mg, 300 mg and 600 mg.
Trileptal is a widely used medication to treat epilepsy that has FDA approval.